BYSI · XBRL financial data

BeyondSpring financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BYSI's year ends in late December)

In thousands of dollars	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	31,342	41,793	36,888	25,582	2,644	4,388
Selling, general and administrative	8,965	22,598	30,703	13,008	6,110	4,557
General and administrative	8,965	—	—	—	—	—
Operating income (loss)	(40,307)	(64,211)	(66,240)	(37,239)	(8,754)	(8,945)
Interest income	184	116	98	195	59	78
Interest expense	206	85	87	17	—	—
Other income (expense)	0	4	1,360	1,122	—	—
Income tax expense (benefit)	0	0	3,570	163	(96)	90
Net income (loss)	(38,085)	(60,973)	(64,179)	(33,279)	(11,123)	(1,006)
Earnings per share, basic USD per share	—	(2.03)	(1.64)	(0.85)	(0.28)	(0.02)
Weighted average shares, basic thousands of shares	—	29,984	39,024	39,093	—	—

Fiscal years (BYSI's year ends in late December)

In thousands of dollars	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	35,933	109,537	41,625	34,396	2,922	7,786
Short-term investments	—	0	30,743	2,872	0	4,775
Prepaid and other current assets	410	358	1,020	763	68	71
Total current assets	40,862	113,400	75,123	38,523	28,577	20,882
Property and equipment, net	209	184	1,422	1,868	239	166
Right-of-use asset	2,538	2,174	1,984	5,484	513	305
Total assets	44,555	117,038	81,648	46,222	34,315	25,933
Accounts payable	2,537	2,216	1,656	1,081	295	363
Accrued liabilities	5,861	5,607	3,858	2,470	840	938
Current portion of long-term debt	—	0	1,569	0	—	—
Total current liabilities	10,053	13,766	15,155	7,352	11,010	13,576
Long-term debt	1,436	2,167	0	—	—	—
Lease liability, non-current	1,935	1,359	1,468	3,995	307	0
Total liabilities	13,424	25,217	55,271	49,229	48,600	49,923
Accumulated deficit	(216,845)	(277,818)	(341,997)	(375,276)	(407,425)	(408,431)
Total stockholders' equity	30,277	88,340	26,684	(5,979)	(32,900)	(32,161)
Total liabilities and equity	44,555	117,038	81,648	46,222	34,315	25,933
Common shares outstanding (cover page) thousands of shares	27,886	39,142	38,928	39,000	40,316	41,120

Fiscal years (BYSI's year ends in late December)

In thousands of dollars	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(38,085)	(60,973)	(64,179)	(33,279)	(11,123)	(1,006)
Stock-based compensation	2,101	8,194	3,152	1,666	2,255	722
Net cash from operating activities	(48,162)	(43,745)	(47,242)	(27,464)	(16,443)	(19,769)
Purchases of property and equipment	4	52	2,844	34	224	50
Net cash from investing activities	(4)	(52)	(20,413)	17,560	(12,012)	10,787
Proceeds from issuing common stock	69,454	112,577	0	0	3,000	2,000
Net cash from financing activities	80,171	117,835	1	3,431	26,785	4,968
Net change in cash	32,044	73,604	(67,912)	(7,229)	(1,703)	(3,909)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
BeyondSpring	2,697	not reported	(3,772)*	41.1M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Seres Therapeutics	15,594	736	(22,394)*	9.9M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Oncolytics Biotech	4,115	not reported	(8,138)*	127.5M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Gyre Therapeutics	43,287	29,105	(16,728)*	111.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Volitionrx	2,800	399	(5,160)*	13.6M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Macrogenics	113,907	32,832	(40,748)*	63.7M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Inovio Pharmaceuticals	31,526	0	(18,047)*	103.4M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.